DrugPatentWatch Database Preview
Kaleo Inc Company Profile
What is the competitive landscape for KALEO INC, and when can generic versions of KALEO INC drugs launch?
There are twenty-nine US patents protecting KALEO INC drugs.
There are one hundred and thirty-two patent family members on KALEO INC drugs in fifteen countries and one supplementary protection certificate in one country.
Summary for Kaleo Inc
| International Patents: | 132 |
| US Patents: | 29 |
| Tradenames: | 2 |
| Ingredients: | 2 |
| NDAs: | 3 |
Drugs and US Patents for Kaleo Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kaleo Inc | AUVI-Q | epinephrine | SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS | 201739-003 | Nov 17, 2017 | RX | Yes | No | 8,231,573 | ➤ Try a Free Trial | Y | ➤ Try a Free Trial | |||
| Kaleo Inc | AUVI-Q | epinephrine | SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS | 201739-001 | Aug 10, 2012 | BX | RX | Yes | No | 8,206,360 | ➤ Try a Free Trial | Y | ➤ Try a Free Trial | ||
| Kaleo Inc | AUVI-Q | epinephrine | SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS | 201739-002 | Aug 10, 2012 | BX | RX | Yes | Yes | 8,226,610 | ➤ Try a Free Trial | Y | ➤ Try a Free Trial | ||
| Kaleo Inc | EVZIO | naloxone hydrochloride | SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS | 205787-001 | Apr 3, 2014 | DISCN | Yes | No | 9,022,022 | ➤ Try a Free Trial | Y | ➤ Try a Free Trial | |||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Non-Orange Book US Patents for Kaleo Inc
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 8,361,026 | Apparatus and methods for self-administration of vaccines and other medicaments | ➤ Try a Free Trial |
| 7,648,483 | Devices, systems and methods for medicament delivery | ➤ Try a Free Trial |
| 7,416,540 | Devices systems and methods for medicament delivery | ➤ Try a Free Trial |
| 9,352,091 | Devices, systems and methods for medicament delivery | ➤ Try a Free Trial |
| Patent No. | Title | Estimated Patent Expiration |
International Patents for Kaleo Inc Drugs
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Canada | 2669616 | ➤ Try a Free Trial |
| World Intellectual Property Organization (WIPO) | 2012103303 | ➤ Try a Free Trial |
| United Kingdom | 0910105 | ➤ Try a Free Trial |
| Canada | 2926365 | ➤ Try a Free Trial |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for Kaleo Inc Drugs
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 292 | Luxembourg | ➤ Try a Free Trial | PRODUCT NAME: COMBINAISON D OXYCODONE EN TANT QUE COMPOSANT A ET DE NALOXONE EN TANT QUE COMPOSANT B SOUS TOUTES LES FORMES PROTEGES PAR LE BREVET DE BASE |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.
